Title:Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer
VOLUME: 13 ISSUE: 6
Author(s):Manav Malhotra, Richa Dhingra, Tina Sharma, Aakash Deep, Balasubramanian Narasimhan, Priyanka Phogat and Prabodh Chander Sharma
Affiliation:Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak-124001, Haryana, India.
Keywords:Prostate cancer, Jevtana, Sanofi-aventis, Taxanes, Cabazitaxel, XRP-6258
Abstract:Cabazitaxel has recently been approved by FDA for the treatment of docetaxel resistant hormone-refractory
prostate cancer. It has been developed by Sanofi-Aventis under the trade name of Jevtana. It is given in combination with
prednisone/prednisolone and has passed the clinical trial over well-known drug mitoxantrone. This drug is a microtubule
depolymerization inhibitor, which can penetrate blood brain barrier (BBB). The FDA granted fast track designation to this
drug in November 2009 and thereafter, new drug application submission was done in March 2010. Priority review to this
drug was granted in April 2010 and finally in July 2010 it was approved by FDA. It is available in the form of injection in
the dose of 60 mg/1.5 mL, which should be diluted prior to its use by the diluents supplied along with the injection. It is a
second-line drug and has proven to be effective in patients experiencing docetaxel based treatment failure.
